InMed Pharmaceuticals Inc. (INM) stock
INMNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as MTRI
$1.37+0.05 (+3.44%)
Close on Oct 19, 2026Market cap $83.97MP/E –Yield –
InMed Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
InMed Pharmaceuticals's operating income for the twelve months ending Sep 30, 2023 was -$6.97M. For fiscal 2023 it was -$7.95M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | -$7.95M | – |
| FY2022 | Jun 30, 2022 | -$18.60M | – |
| FY2021 | Jun 30, 2021 | -$10.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$2.54M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$338.39K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$2.00M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$2.10M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$3.51M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$7.87M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$3.48M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$4.28M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$2.97M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$3.26M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$3.10M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$2.24M | – |
See a number that looks wrong?